Prospects of the impact of antihypertensive therapy on the pathogenetic mechanisms of insulin resistance

Abstract

The study was undertaken to evaluate the antihypertensive effectiveness and metabolic safety of the selective imidazoline receptor agonist moxonidine. Thirty patients with mild and moderate arterial hypertension associated with type 2 diabetes mellitus were ex-amined. The patients' mean age was S2.43±4.65 years. The history of diabetes mellitus and arterial hypetension averaged 4.77±2.69 and 6.93±2.98 years, respectively. The duration of the study was 16 weeks. The drug was found to have a positive effect on the 24-hour blood pressure (BP) profile: a long-term significant optimal lowering of DP during 12 hours, a significant reduction in the pressure load index, a decrease of the baseline greater variability, and normalization of a two-phase BP profile. There was a significant improvement of carbohydrate metabolism: a reduction in the level of glycolysated hemoglobin and fasting glycemia, a decrease in the fasting and postprandial immunoreactive insulin levels, which suggests the positive effect of the drug on tissue insulin sensitivity at the level of peripheral tissues and the liver. There was a significant tendency for changing the qualitative composition of blood lipids by lowering the atherogenic fractions of lipoproteins and by elevating the level of high-density lipoproteins. Physiotens is a highly effective antihypertensive drug that may be recommended for the treatment of mild and moderate arterial hypertension in patients with impairments considered within the metabolic syndrome.